HRP20010740B1 - Esters of l-carnitine or alkanoyl l-carnitines use ful as cationic lipids for the intracelular delivery of pharmacologically active compounds - Google Patents

Esters of l-carnitine or alkanoyl l-carnitines use ful as cationic lipids for the intracelular delivery of pharmacologically active compounds

Info

Publication number
HRP20010740B1
HRP20010740B1 HR20010740A HRP20010740A HRP20010740B1 HR P20010740 B1 HRP20010740 B1 HR P20010740B1 HR 20010740 A HR20010740 A HR 20010740A HR P20010740 A HRP20010740 A HR P20010740A HR P20010740 B1 HRP20010740 B1 HR P20010740B1
Authority
HR
Croatia
Prior art keywords
carnitines
carnitine
alkanoyl
esters
active compounds
Prior art date
Application number
HR20010740A
Other languages
English (en)
Inventor
Pisano Claudio
Ornella Tinti Maria
Santaniello Mose
Critelli Luciana
Salvatori Giovanni
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Publication of HRP20010740A2 publication Critical patent/HRP20010740A2/hr
Publication of HRP20010740B1 publication Critical patent/HRP20010740B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HR20010740A 1999-04-13 2001-10-12 Esters of l-carnitine or alkanoyl l-carnitines use ful as cationic lipids for the intracelular delivery of pharmacologically active compounds HRP20010740B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999RM000220A IT1306129B1 (it) 1999-04-13 1999-04-13 Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
PCT/IT2000/000137 WO2000061543A2 (en) 1999-04-13 2000-04-11 Esters of l-carnitine or alkanoyl l-carnitines

Publications (2)

Publication Number Publication Date
HRP20010740A2 HRP20010740A2 (en) 2002-10-31
HRP20010740B1 true HRP20010740B1 (en) 2005-08-31

Family

ID=11406659

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010740A HRP20010740B1 (en) 1999-04-13 2001-10-12 Esters of l-carnitine or alkanoyl l-carnitines use ful as cationic lipids for the intracelular delivery of pharmacologically active compounds

Country Status (34)

Country Link
US (4) US6797281B1 (ru)
EP (3) EP1435232A1 (ru)
JP (2) JP4703855B2 (ru)
KR (2) KR100684378B1 (ru)
CN (2) CN100402017C (ru)
AT (2) ATE317257T1 (ru)
AU (2) AU776301B2 (ru)
BG (3) BG65501B1 (ru)
BR (2) BR0009765B1 (ru)
CA (2) CA2370143C (ru)
CZ (1) CZ302628B6 (ru)
DE (2) DE60017388T2 (ru)
DK (2) DK1426044T3 (ru)
EA (2) EA006021B1 (ru)
EE (2) EE05719B1 (ru)
ES (2) ES2234591T3 (ru)
HK (2) HK1045145B (ru)
HR (1) HRP20010740B1 (ru)
HU (1) HU229366B1 (ru)
IL (4) IL145765A0 (ru)
IS (2) IS2476B (ru)
IT (1) IT1306129B1 (ru)
ME (2) ME00113B (ru)
MX (1) MXPA01010359A (ru)
NO (2) NO327742B1 (ru)
NZ (2) NZ528874A (ru)
PL (2) PL204418B1 (ru)
PT (2) PT1426044E (ru)
RS (3) RS20090448A (ru)
SI (2) SI1183228T1 (ru)
SK (2) SK287253B6 (ru)
TR (2) TR200102941T2 (ru)
WO (1) WO2000061543A2 (ru)
ZA (1) ZA200109291B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1246792B1 (en) * 2000-01-13 2014-08-13 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DE10113446A1 (de) † 2001-03-19 2002-09-26 Schwarzkopf Gmbh Hans Haarbehandlungsmittel mit Betainen
PT2108362E (pt) * 2002-06-26 2013-07-11 Medigene Ag Preparação lipossomal catiónica que compreende um taxano
WO2004002468A1 (en) 2002-06-26 2004-01-08 Medigene Oncology Gmbh Method of producing a cationic liposomal preparation comprising a lipophilic compound
ITRM20040288A1 (it) * 2004-06-11 2004-09-11 Sigma Tau Ind Farmaceuti Uso della 7-t-butossiimminometilcamptotecina per la preparazione di un medicamento per il trattamento delle neoplasie dell'utero.
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos
US20080095834A1 (en) * 2005-03-02 2008-04-24 Volkmar Weissig Mitochondriotropic Phospholipid Vesicles
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
TW200800195A (en) * 2005-08-10 2008-01-01 Novartis Ag Organic compounds
MX2008001970A (es) * 2005-08-10 2008-03-24 Novartis Ag Formulaciones para 7-(t-butoxi)iminometil camptotecin.
WO2008024389A2 (en) * 2006-08-23 2008-02-28 Biodelivery Sciences International, Inc. Amphiphilic nucleotide cochleate compositions and methods of using the same
WO2008094959A1 (en) * 2007-02-01 2008-08-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition comprising a campothecin derivative
WO2008101173A2 (en) * 2007-02-16 2008-08-21 Cornell University Biodegradable compositions and materials
US20100204432A1 (en) 2007-05-28 2010-08-12 Husam Younes Biodegradable elastomers prepared by the condensation of an organic di-, tri- or tetra-carboxylic acid and an organic diol
WO2008154484A1 (en) 2007-06-08 2008-12-18 Mannkind Corporation Ire-1a inhibitors
AU2009223222A1 (en) 2008-03-13 2009-09-17 Perkinelmer Health Sciences, Inc. Enzymatic substrates for multiple detection systems
EP2532649B1 (en) * 2011-06-07 2015-04-08 Incella GmbH Amino lipids, their synthesis and uses thereof
WO2013032643A2 (en) * 2011-08-31 2013-03-07 Dicerna Pharmaceuticals, Inc. Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells
US20140274798A1 (en) 2013-03-15 2014-09-18 University Of Washington Through Its Center For Commercialization Compounds and methods relating to lysosomal storage disorders
US11376324B2 (en) 2016-03-02 2022-07-05 The Board Of Regents Of The University Of Texas System Sting activating nanovaccine for immunotherapy
CN110997624B (zh) 2017-06-06 2024-05-24 韦恩州立大学 与肉毒碱衍生的材料相关的方法和组合物
CN115177608B (zh) * 2022-07-26 2023-12-05 南方医科大学南方医院 长链酰基肉碱类化合物在制备预防和/或治疗肝癌的药物中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866040A (en) * 1986-01-06 1989-09-12 Alfred Stracher Aminocarnitine directed pharmaceutical agents
US5008288A (en) * 1986-01-06 1991-04-16 Alfred Stracher Carnitine directed pharmaceutical agents
IT1230142B (it) * 1989-05-03 1991-10-14 Fidia Spa Derivati della carnitina, processo per la loro preparazione e impiego in terapia umana
DE69119074T2 (de) * 1990-06-15 1996-12-12 University Of North Carolina At Chapel Hill, Chapel Hill, N.C. Kovalente-ther lipidnukleosid-konjugate
IT1248321B (it) * 1991-05-15 1995-01-05 Sigma Tau Ind Farmaceuti Uso di esteri di acil l-carnitine con l'acido gamma-idrossibutirrico per produrre composizioni farmaceutiche per il trattamento di epatopatie
IT1258370B (it) * 1992-03-02 1996-02-26 Sigma Tau Ind Farmaceuti Esteri della l-carnitina e di acil l-carnitine dotati di attivita' miorilassante selettiva sull'apparato gastro-intestinale e composizioni farmaceutiche che li contengono.
US5972600A (en) * 1992-04-03 1999-10-26 The Regents Of The University Of California Separation of active complexes
IT1263013B (it) * 1992-10-20 1996-07-23 Avantgarde Spa Esteri della l-carnitina e di alcanoil l-carnitine con l'acido glicolico o suoi esteri e composizioni farmaceutiche contenenti tali per il trattamento di affezioni cutanee.
US5552156A (en) * 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
US5512671A (en) * 1993-02-16 1996-04-30 Wake Forest University Ether lipid-nucleoside covalent conjugates
IT1261984B (it) * 1993-06-22 1996-06-11 Avantgarde Spa Uso di esteri della l-carnitina o di acil l- carnitine con idrossiacidi per produrre composizioni farmaceutiche per il trattamento di affezioni cutanee.
DE69407292T2 (de) * 1993-06-30 1998-06-25 Genentech Inc Verfahren zur herstellung von liposomen
IT1273987B (it) * 1994-09-29 1997-07-14 Sigma Tau Ind Farmaceuti Uso di esteri ftalidilidenici della carnitina e di alcanoil carnitine per il trattamento dello shock endotossico
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6316652B1 (en) * 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
JP2001516329A (ja) * 1995-06-07 2001-09-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ポリヌクレオチド複合体の安定化
US5811406A (en) * 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
IT1283955B1 (it) * 1996-03-20 1998-05-07 Sigma Tau Ind Farmaceuti Bis alcanoil esteri della carnitina ad attivita' antibatterica, antimicotica ed antiprotozoaria.
WO1998004720A1 (en) * 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6071532A (en) * 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
IT1299172B1 (it) * 1998-05-06 2000-02-29 Sigma Tau Ind Farmaceuti Esteri perfluorurati di alcanoil l-carnitine utilizzabili quali lipidi cationici per l'immissione intracellulare di composti

Also Published As

Publication number Publication date
YU70201A (sh) 2004-07-15
BR0009765A (pt) 2002-01-02
IL175366A (en) 2010-12-30
ES2258688T3 (es) 2006-09-01
KR100684378B1 (ko) 2007-02-20
EA200300745A1 (ru) 2003-12-25
EA006021B1 (ru) 2005-08-25
DK1183228T3 (da) 2005-05-17
ATE317257T1 (de) 2006-02-15
TR200102941T2 (tr) 2002-05-21
KR100798499B1 (ko) 2008-01-28
PL211710B1 (pl) 2012-06-29
EP1426044B1 (en) 2006-02-08
HK1045145B (zh) 2006-01-27
EP1183228B1 (en) 2005-01-12
RS50911B (sr) 2010-08-31
EE05719B1 (et) 2014-08-15
SI1183228T1 (en) 2005-04-30
IS2539B (is) 2009-09-15
AU776301B2 (en) 2004-09-02
JP2002541238A (ja) 2002-12-03
BR0009765B1 (pt) 2013-11-05
AU2004224958B2 (en) 2007-11-22
BG109876A (en) 2008-02-29
US20070190128A1 (en) 2007-08-16
IS2476B (is) 2008-12-15
DK1426044T3 (da) 2006-06-12
BG105971A (en) 2002-08-30
US6797281B1 (en) 2004-09-28
EE201100028A (et) 2011-08-15
PT1183228E (pt) 2005-04-29
CN1359370A (zh) 2002-07-17
MXPA01010359A (es) 2002-05-06
US20040186175A1 (en) 2004-09-23
SK287253B6 (sk) 2010-04-07
IL175366A0 (en) 2006-09-05
JP2011042657A (ja) 2011-03-03
EE200100518A (et) 2002-12-16
EP1426044A1 (en) 2004-06-09
ITRM990220A1 (it) 2000-10-13
HK1045145A1 (en) 2002-11-15
WO2000061543A3 (en) 2001-01-11
CA2370143A1 (en) 2000-10-19
EA200101076A1 (ru) 2002-04-25
NO327742B1 (no) 2009-09-14
PL204418B1 (pl) 2010-01-29
DE60025961T2 (de) 2006-08-17
NO336949B1 (no) 2015-11-30
TR200202358T2 (tr) 2002-12-23
DE60017388D1 (de) 2005-02-17
MEP24008A (en) 2010-06-10
DE60017388T2 (de) 2006-03-30
IL145765A0 (en) 2002-07-25
EP1435232A1 (en) 2004-07-07
KR20060113799A (ko) 2006-11-02
DE60025961D1 (de) 2006-04-20
NO20014985D0 (no) 2001-10-12
BRPI0017460B1 (pt) 2016-04-19
EA004459B1 (ru) 2004-04-29
AU4312300A (en) 2000-11-14
CN100402017C (zh) 2008-07-16
EE05514B1 (et) 2012-02-15
CN1823731A (zh) 2006-08-30
PT1426044E (pt) 2006-06-30
NZ528874A (en) 2005-09-30
KR20010113794A (ko) 2001-12-28
CA2650202C (en) 2012-12-11
CZ302628B6 (cs) 2011-08-10
IT1306129B1 (it) 2001-05-30
HK1092732A1 (en) 2007-02-16
ZA200109291B (en) 2002-08-16
IS8719A (is) 2008-03-07
ATE286873T1 (de) 2005-01-15
JP5420507B2 (ja) 2014-02-19
NZ515270A (en) 2004-02-27
PL351112A1 (en) 2003-03-24
AU2004224958A1 (en) 2004-11-25
BG65312B1 (bg) 2008-01-31
HUP0201446A2 (en) 2002-08-28
IL185486A0 (en) 2008-01-06
HU229366B1 (en) 2013-11-28
HUP0201446A3 (en) 2002-11-28
EP1183228A2 (en) 2002-03-06
SI1426044T1 (sl) 2006-04-30
CA2650202A1 (en) 2000-10-19
US20050079209A1 (en) 2005-04-14
HRP20010740A2 (en) 2002-10-31
JP4703855B2 (ja) 2011-06-15
SK14312001A3 (sk) 2002-02-05
IL145765A (en) 2007-07-04
RS52682B (en) 2013-08-30
WO2000061543A2 (en) 2000-10-19
IS6095A (is) 2001-09-28
RS20090448A (en) 2010-06-30
CN1263730C (zh) 2006-07-12
US7585519B2 (en) 2009-09-08
CA2370143C (en) 2011-06-21
CZ20013617A3 (cs) 2002-02-13
BG65501B1 (bg) 2008-10-31
NO20085413L (no) 2001-10-12
NO20014985L (no) 2001-10-12
ME00113B (me) 2010-10-10
US7629003B2 (en) 2009-12-08
SK288246B6 (sk) 2015-03-03
ES2234591T3 (es) 2005-07-01

Similar Documents

Publication Publication Date Title
IL185486A0 (en) Esters of l-carnitine or alkanoyl l-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds
AU3900299A (en) Cationic lipids with disulphide bonds for the intracellular delivery of therapeutic substances
AU3669700A (en) 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient
AU3846599A (en) Perfluorinated esters of alkanoyl l-carnitine for the preparation of cationic lipids for the intracellular delivery of pharmacologically active compounds

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20160323

Year of fee payment: 17

PBON Lapse due to non-payment of renewal fee

Effective date: 20170411